Phase III Plans in the Works
Cytokinetics’ Phase II HF Data: Traders Skeptical, Amgen Not
By Randy Osborne
Wednesday, September 4, 2013
Cytokinetics Inc. and licensor Amgen Inc. will wait until a Phase II study in chronic heart failure with orally given omecamtiv mecarbil generates data to decide the fate of the compound, which fizzled in a Phase II trial testing the intravenous (I.V.) form of the cardiac myosin activator against acute heart failure (AHF).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.